Horizon Discovery Collaborates with a Top Three Pharmaceutical Company

Horizon Discovery Group, an innovator in the application of gene editing technologies, have announced the signing of a Master Services Agreement (MSA) with a top three global pharmaceutical company, extending support for their drug discovery and development efforts to Horizon’s full suite of services.

Adding to a pre-existing MSA for in vivo services, the terms of this agreement now cover a range of Horizon’s in vitro service offerings, defining the pricing and terms that will govern future transactions and facilitating simplified entry into forthcoming agreements. Services included under the MSA are: custom cell line engineering, target identification and validation screening (including the use of CRISPR gene editing technology), drug combination screening, and cell-based assay services.

Horizon is establishing itself as a key provider to an increasing number of major pharmaceutical and biotech companies by delivering reliable, high-quality, high-value services, and by strengthening key relationships within each organisation. In this way, Horizon was able to negotiate this agreement, building trust with the Company and becoming a preferred provider over time. It is now Horizon’s single largest customer, contributing over £1.5 million in revenue in 2016 (c£0.6 million FY15) and the current project pipeline indicates there will be an expansion of revenue received in 2017.